Tag Archives: Lilly
Fixing Innovation: Lilly's CEO Says Why, and How
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing Also tagged CEO, CEOs, drug safety, Eli Lilly, Financial Times, Global, healthcare reform, innovation, IP, IPAB, PhRMA, policy, R&D 1 Comment
CETP Inhibitors: Blockbusters that Never Ran?
The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.
Posted in Biotech, R&D, Technology, leadership Also tagged Biotech, Biotechnology and Pharmaceuticals, Cardiovascular disease, CETP Inhibitors, Merck, Resverlogix, Roche Leave a comment
Saving Haiti: One Donation at a Time (UPDATED 1/21)
Image by American Red Cross via Flickr
It’s been less than three days since new broke of a massive earthquake in Haiti that all but leveled the struggling country. With thousands dead, a devastated infrastructure, and no emergency plan, countries and businesses around the world have joined in the effort to help the Haitian people with [...]
Posted in News Also tagged Abbott, American Red Cross, Amgen, Emergency management, Haiti, Health care, Humanitarian aid, Red Cross 2 Comments
Lilly Osteoporosis Drug Canned in Phase III Trials
Image by go elsewhere… via Flickr
Lilly, on Wednesday, announced that it would not seek regulatory approval for its osteoporosis treatment arzoxifene, because the drug failed to meet certain end points in Phase III clinical trials.
The good news is that the drug was successful in meeting the primary end point of the trial, dubbed “GENERATIONS.†[...]
Posted in Strategy Also tagged arzoxifene, Breast cancer, Clinical trial, GENERATIONS, Osteoporosis drug market, U.S. Food and Drug Administration 1 Comment

Is There a Global Policy Gap on Cancer?